Results 191 to 200 of about 55,714 (316)

Genetic alterations in hepatocellular carcinoma after sustained virological response in relation to the molecular characterization of metabolic diseases

Hepatology Research, EarlyView.
Hepatocellular carcinoma (HCC) in the hepatitis C virus (HCV)‐sustained virologic response (SVR) group was associated with alcohol consumption and metabolic diseases and showed significantly lower rates of ARID2 alterations and AXIN1 alterations compared to the HCV‐non‐SVR group, with a mutational profile resembling that of the steatotic liver disease ...
Fukiko Kawai‐Kitahata, Yasuhiro Asahina, Sei Kakinuma, Kento Inada, Tomohiro Mochida, Keiya Watakabe, Tsubasa Nobusawa, Taro Shimizu, Jun Tsuchiya, Masato Miyoshi, Shun Kaneko, Miyako Murakawa, Sayuri Nitta, Mina Nakagawa, Yuko Kinowaki, Daisuke Ban, Shinji Tanaka, Tatsuhiko Anzai, Shinichi Takano, Shinya Maekawa, Nobuyuki Enomoto, Ryuichi Okamoto   +21 more
wiley   +1 more source

Dynamic changes of chronic hepatitis B patient with loss of surface antigen: a case report. [PDF]

BMC Infect Dis
Wang C, Lin L, Ding DP.
europepmc   +1 more source

Predicting the risk of developing diabetes in steatotic liver disease using controlled attenuation parameter in a health checkup population

Hepatology Research, EarlyView.
Higher amounts of liver fat, measured noninvasively using the controlled attenuation parameter (CAP), are a strong predictor of the future development of type 2 diabetes mellitus. The risk increases in proportion to the increase in CAP. Measuring CAP could help identify individuals who need diabetes prevention strategies.
Takuma Nakatsuka, Yutaka Yamaji, Ryosuke Tateishi, Takako Ogasawara, Rena Mihara, Yoshiaki Kawashima, Tetsuharu Ono, Tomoharu Yamada, Tatsuya Minami, Masaya Sato, Takeshi Hayashi, Yuki Matsushita, Kazuyoshi Funato, Tatsuya Sato, Tomotaka Saito, Yotaro Kudo, Hirofumi Kogure, Hayato Nakagawa, Yoshinari Asaoka, Yasuo Tanaka, Yousuke Nakai, Hideaki Ijichi, Mitsuhiro Fujishiro   +22 more
wiley   +1 more source

Glycoengineering of the hepatitis C virus E2 glycoprotein improves biochemical properties and enhances immunogenicity. [PDF]

NPJ Vaccines
Kulakova L, Li KH, Chiang AWT, Schwoerer MP, Suzuki S, Schoffelen S, Elkholy KH, Chao KL, Shahid S, Kumar B, Murray NB, Archer-Hartmann S, Azadi P, Voldborg BG, Marin A, Mariuzza RA, Andrianov AK, Ploss A, Lewis NE, Toth EA, Fuerst TR.   +20 more
europepmc   +1 more source

The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long‐Term Administration of Nucleos(t)ide Analogs

Hepatology Research, EarlyView.
The risk of HCC persists long after NUC initiation. In noncirrhotic patients, the risk remains stable more than 10 years after NUC treatment initiation. ABSTRACT Background and Aim Nucleos(t)ide analogs (NUCs) are used in the treatment of chronic hepatitis B (CHB).
Kazuhiro Murai, Hayato Hikita, Ryoko Yamada, Yuki Nishimura, Masanori Miyazaki, Hisashi Ishida, Atsushi Hosui, Ryotaro Sakamori, Nobuyuki Tatsumi, Kazuyoshi Ohkawa, Yoshinori Doi, Takatoshi Nawa, Satoshi Egawa, Yuichi Yoshida, Yasutoshi Nozaki, Kazuho Imanaka, Masanori Nakahara, Mitsuru Sakakibara, Takayuki Yakushijin, Hiroyuki Ogawa, Takeo Usui, Kengo Matsumoto, Tsugiko Oze, Shinji Kuriki, Emi Sometani, Jihyun Sung, Akiyoshi Shimoda, Satoshi Shigeno, Kazuki Maesaka, Kumiko Shirai, Akira Doi, Yuki Tahata, Yoshinobu Saito, Takahiro Kodama, Tomohide Tatsumi, Tomomi Yamada, Tetsuo Takehara   +36 more
wiley   +1 more source

The status of occult HBV infection in a high endemic region: risk of community HBV transmission and reactivation. [PDF]

BMC Res Notes
Kafeero HM, Ocama P, Ndagire D, Walusansa A, Namusoke M, Kudamba A, Muwanda F, Sendagire H.   +7 more
europepmc   +1 more source

Continuous Intravenous Infusion of Hepatocyte Growth Factor Promotes the Development of a Fibrolytic Phenotype in Hepatic Macrophages and Stellate Cells in a Rat Model of Bile Duct Ligation

Hepatology Research, EarlyView.
This study demonstrates that continuous intravenous infusion of hepatocyte growth factor can significantly reduce liver fibrosis in rats. This treatment promotes hepatocyte regeneration and reduces harmful inflammation, offering promising potential as a therapy for liver cirrhosis in humans. ABSTRACT Aim Liver cirrhosis is a severe condition that often
Oki Taniyama, Kotaro Kumagai, Shuji Kanmura, Yuko Nakamura, Hiromi Eguchi, Miho Uehara, Kyoko Meguro, Ai Toyodome, Sho Ijuin, Haruka Sakae, Kazuaki Tabu, Kohei Oda, Seiichi Mawatari, Keisuke Yano, Satoshi Ieiri, Akio Ido   +15 more
wiley   +1 more source

Hepatitis B virus infection among children aged 1- 5 years of Mayurbhanj district (Odisha), India: A prospective study protocol. [PDF]

PLoS One
Bhat KD, Bhattacharya H, Jayaraman Y, Kanungo S, Pattnaik M, Pati S, Bhattacharya D.   +6 more
europepmc   +1 more source

Elevation of Immunoglobulin Free Light Chain and BAFF Levels Associated With Immune Activation Predicts Survival Rates in Chronic Liver Disease

Hepatology Research, EarlyView.
ABSTRACT Aims Elevated serum free light chain (FLC) and B‐cell activating factor (BAFF) levels have been reported to be associated with B‐cell activation and to serve as biomarkers reflecting disease severity in various diseases. However, limited investigation has been conducted in the context of chronic liver disease (CLD), and the aim of this study ...
Motoh Iwasa, Akiko Eguchi, Yasuyuki Tamai, Ryuta Shigefuku, Hideaki Tanaka, Ryo Nakagawa, Mina Tempaku, Yoshinao Kobayashi, Hayato Nakagawa   +8 more
wiley   +1 more source

Distinct H-2-linked regulation of T-cell responses to the pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S region.

, 1985
David R. Milich, M McNamara, A. McLachlan, George B. Thornton, Francis V. Chisari   +4 more
openalex   +1 more source